西方多中心回顾性研究:腹腔镜胃切除术治疗II-III期进展期胃癌的长期随访数据
本研究回顾性分析2005年至2019年间七家西方外科中心连续收治的366例II-III期进展期胃癌患者,均行腹腔镜胃切除+D2淋巴结清扫。主要终点为无病生存期,5年DFS为0.62(95%CI 0.55-0.69),5年OS为0.63(95%CI 0.56-0.71),认为由培训有素的外科医生实施时该术式在西方常规实践中可行且安全。
要点
- II-III期进展期胃癌行腹腔镜胃切除+D2淋巴结清扫,5年DFS为0.62(95%CI 0.55-0.69)。
- 5年OS为0.63(95%CI 0.56-0.71),中位随访36±16个月。
- 术后总体并发症率27.32%,严重并发症(Clavien-Dindo≥III级)占9.29%。
核心结论
- 在西方机构常规实践中,由培训有素的外科医生实施腹腔镜胃切除治疗进展期胃癌是可行且安全的。
研究设计与样本
- 主要终点为无病生存期(DFS),次要终点包括总生存期(OS)、淋巴结清扫数目、术后并发症率和中转开腹率。
主要发现
- 平均清扫淋巴结数为25±14枚,平均住院日13±10天。
- 术后总体并发症率为27.32%,严重并发症(≥III级)占9.29%。
- 中位随访36±16个月,期间90例死亡,均死于疾病进展。
- 1年DFS为0.85(95%CI 0.81-0.89),5年DFS为0.62(95%CI 0.55-0.69)。
- 1年OS为0.94(95%CI 0.92-0.97),5年OS为0.63(95%CI 0.56-0.71)。
临床怎么用
- 对于II-III期进展期胃癌,在具备经验的西方中心可考虑腹腔镜胃切除+D2淋巴结清扫,但需由培训有素的外科医生实施。
- 术前应与患者充分沟通5年DFS约62%、5年OS约63%的长期生存预期及27.32%的总体并发症风险。
- 术中应保证足够的淋巴结清扫数目(本研究平均25枚)以保障肿瘤学质量。
局限性
- 回顾性研究设计,可能存在选择偏倚和信息偏倚。
- 仅纳入西方七家中心病例,结果外推至其他地区或机构需谨慎。
- 未报告中转开腹率的具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There has been an increasing interest for the laparoscopic treatment of early gastric cancer, especially among Eastern surgeons. However, the oncological effectiveness of Laparoscopic Gastrectomy (LG) for Advanced Gastric Cancer (AGC) remains a subject of debate, especially in Western countries where limited reports have been published. The aim of this paper is to retrospectively analyze short- and long-term results of LG for AGC in a real-life Western practice. MATERIALS AND METHODS: All consecutive cases of LG with D2 lymphadenectomy for AGC performed from January 2005 to December 2019 at seven different surgical departments were analyzed retrospectively. The primary outcome was diseases-free survival (DFS). Secondary outcomes were overall survival (OS), number of retrieved lymph nodes, postoperative morbidity and conversion rate. RESULTS: A total of 366 patients with stage II and III AGC underwent either total or subtotal LG. The mean number of harvested lymph nodes was 25 ± 14. The mean hospital stay was 13 ± 10 days and overall postoperative morbidity rate 27.32%, with severe complications (grade ≥ III) accounting for 9.29%. The median follow-up was 36 ± 16 months during which 90 deaths occurred, all due to disease progression. The DFS and OS probability was equal to 0.85 (95% CI 0.81-0.89) and 0.94 (95% CI 0.92-0.97) at 1 year, 0.62 (95% CI 0.55-0.69) and 0.63 (95% CI 0.56-0.71) at 5 years, respectively. CONCLUSION: Our study has led us to conclude that LG for AGC is feasible and safe in the general practice of Western institutions when performed by trained surgeons.
引用
- Bracale U, Merola G, Pignata G, et al. Laparoscopic gastrectomy for stage II and III advanced gastric cancer: long‑term follow‑up data from a Western multicenter retrospective study. Surg Endosc. 2021. PMID: 33877411. doi:10.1007/s00464-021-08505-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。